Exicure, Inc. XCUR
We take great care to ensure that the data presented and summarized in this overview for EXICURE, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding XCUR
View all-
Abingworth LLP London, X0282KShares$844,9080.11% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA46KShares$138,0060.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA40.1KShares$120,2790.0% of portfolio
-
Ubs Group Ag17.3KShares$51,9330.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny14.9KShares$44,7000.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny12KShares$36,0870.0% of portfolio
-
Tower Research Capital LLC (Trc) New York, NY7.18KShares$21,5490.0% of portfolio
-
Black Rock Inc. New York, NY5.11KShares$15,3390.0% of portfolio
-
Morgan Stanley New York, NY3.07KShares$9,2160.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ289Shares$8670.0% of portfolio
Latest Institutional Activity in XCUR
Top Purchases
Top Sells
About XCUR
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Insider Transactions at XCUR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 12
2024
|
Dgp Co., Ltd. |
BUY
Open market or private purchase
|
Direct |
237,223
+21.83%
|
$711,669
$3.0 P/Share
|
|
Aug 16
2024
|
Josh Miller Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
38
-2.13%
|
$0
$0.36 P/Share
|
|
May 16
2024
|
Josh Miller Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
46
-2.52%
|
$0
$0.52 P/Share
|
|
Feb 29
2024
|
Dgp Co., Ltd. |
SELL
Open market or private sale
|
Direct |
3,400,000
-100.0%
|
$3,400,000
$1.32 P/Share
|
|
Feb 16
2024
|
Josh Miller Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
46
-2.46%
|
$0
$0.6 P/Share
|
|
Nov 16
2023
|
Josh Miller Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
38
-1.99%
|
$0
$0.56 P/Share
|
|
Aug 16
2023
|
Josh Miller Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
37
-1.9%
|
$0
$0.83 P/Share
|
|
Jun 23
2023
|
Cbi Usa, Inc. |
SELL
Conversion of derivative security
|
Direct |
3,400,000
-80.6%
|
$3,400,000
$1.6 P/Share
|
|
May 16
2023
|
Josh Miller Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
185
-8.67%
|
$185
$1.07 P/Share
|
|
Dec 15
2022
|
Cbi Usa, Inc. |
BUY
Open market or private purchase
|
Direct |
3,400,000
+44.63%
|
$3,400,000
$1.6 P/Share
|
|
May 19
2022
|
Bali Muralidhar Director |
BUY
Open market or private purchase
|
Indirect |
1,472,126
+14.84%
|
$0
$0.19 P/Share
|
|
Dec 21
2021
|
Gates Frontier, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,268,619
-20.03%
|
$0
$0.24 P/Share
|
|
Nov 15
2021
|
Douglas E. Feltner Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+33.33%
|
$0
$0.91 P/Share
|
|
Nov 15
2021
|
David A Giljohann Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+16.25%
|
$0
$0.91 P/Share
|
|
Aug 27
2021
|
Elias D. Papadimas Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
10,000
+50.0%
|
$10,000
$1.38 P/Share
|
|
May 14
2021
|
Douglas E. Feltner Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+50.0%
|
$7,500
$1.27 P/Share
|
|
May 14
2021
|
David A Giljohann Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+19.4%
|
$7,500
$1.27 P/Share
|
|
May 14
2021
|
Matthias Schroff Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+50.0%
|
$7,500
$1.27 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 237K shares |
|---|
| Payment of exercise price or tax liability | 168 shares |
|---|---|
| Open market or private sale | 3.4M shares |